Welcome to Sloan Kettering Institute

The Sloan Kettering Institute (SKI) is the basic and translational research arm of Memorial Sloan Kettering Cancer Center. Discoveries made in SKI labs are an important driver of clinical progress at MSK and beyond. Our research spans nine program areas: 

Find a researcher from one of our labs.
View all SKI labs
This Is SKI
Discover how SKI is moving cancer science forward.

A Collaborative Approach 

Collaboration is a hallmark of the research enterprise at SKI. Our scientists collaborate across programs, across disciplines, and across institutions.

Collaborative Research Centers
Researchers from SKI and Memorial Hospital join forces in 23 established Collaborative Research Centers. These centers bring together laboratory scientists and clinicians to spark innovation.

Joint Graduate Programs
SKI enjoys close relationships with neighbors Rockefeller University and Weill Cornell Medicine, and partners with them in several joint graduate programs.

Tri-Institutional Therapeutics Discovery Institute
This innovative partnership between MSK, Rockefeller, Weill Cornell, and industry aims to speed the translation of basic scientific discoveries into promising new medicines.

The Center for Cancer Systems Immunology brings together faculty from across the Sloan Kettering Institute, such as Alexander Rudensky (left) and Christina Leslie (right).

Immunologist Alexander Rudensky (right) directs the Ludwig Center for Cancer Immunotherapy, one of the collaborative research centers that makes SKI an exciting place to do science.

Featured News and Events View all news View all events
MSK’s Sloan Kettering Institute Celebrates 75 Years of Discovery
Over the last seven and a half decades, researchers at the Sloan Kettering Institute have made important contributions to the fundamental understanding of human biology, as well as driven practice-changing innovations in the treatment of cancer.
MSK Scientists Identify Potential New Strategy Against Metastasis
A team of scientists at the Sloan Kettering Institute has identified the STING cellular signaling pathway as a key player in keeping dormant cancer cells from progressing into aggressive tumors months, or even years, after they’ve escaped from a primary tumor.
Getting Drugs Across the Blood-Brain Barrier Using Nanoparticles
Learn how MSK researchers are investigating the use of nanoparticles to carry drugs across the blood-brain barrier.